Children's healthcare is more than just the Children's Health Insurance Program (CHIP). The area of children's health policy is one that is largely misunderstood, said Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor of Health Law and Policy and founding chair of the Department of Health Policy at the Milken Institute School of Public Health, George Washington University.
Transcript
What is being left out of or not being discussed in any policy debates about children’s healthcare in the US?
The question of sort of how do we think about children’s healthcare, children’s health policy, is one of those issues that has been, I would say, misunderstood for all the years that I have been working on children’s health policy, which is a long time now. We tend to boil it down to CHIP and CHIP, of course, is extremely important and Congress fortunately extended the funding for CHIP back at the very beginning of February now, end of January. And that stabilizes coverage for about 9 million children.
Of course, there are about another 36 million children or so in that part of public insurance that we know as Medicaid and some of the CHIP children are Medicaid children. So, the bigger discussion we are not having is one that takes a step back and looks at the panoramic situation of children and health insurance in the United States today and what you see is that of course we are in a very long, slow, but steady decline in terms of children’s access to their parents plans and this very long shift that began as the decline became apparent towards children in public insurance.
So, the discussion needs to be more than just are we going to fund CHIP, the little slice of public financing, but what can we do to make public insurance for children stronger? How do we make sure children remain stably covered? How do we make sure they get the scope of coverage they need and how do we use financing to generate a movement toward healthcare systems that can interact particularly well with schools, child welfare, and other services that children use?
What lessons do you think we learned form the recent battle over reauthorizing funding for CHIP?
Well, I would say lesson #1 is the next time somebody tries to sell you a Medicaid block grant, think twice. All of the block grant legislation, just like CHIP, tend to be time-regulated blocks that have to be extended and in the CHIP battle which after all was a teeny, tiny program in terms of the overall funding think about what would happen to states if suddenly the ending of a $3 trillion program was reached. What would you do at that point? I would say that the big takeaway lesson is that when the federal government tries to restate its partnership in indogen health care as we will give you some money and get out of your way, don’t believe it.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More